Journey Medical (DERM) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
12 Nov, 2026Executive summary
Q3 revenue rose 8% YoY to $19.0M; Emrosi revenue grew 84% to $9.0M, and adjusted EBITDA was positive for a second consecutive quarter.
9M revenue increased 17% to $53.4M, while net loss narrowed to $3.9M from $10.2M.
Emrosi demand, refill trends, prescriber growth and improving payer reimbursement mix supported momentum.
Financial highlights
Q3 product revenue was $18.9M, up 11% YoY; other revenue fell 93% to $42K as prior-year Cutia supply revenue did not recur.
Q3 GAAP net loss narrowed to $1.315M, or $0.05/share, from $2.315M, or $0.09/share; operating loss narrowed to $530K from $1.5M.
Gross margin was 69% versus 67% in Q3 2025, primarily reflecting Emrosi’s lower cost impact on cost of sales.
SG&A was $12.6M, up $0.5M YoY; it included a one-time $1.7M former-vendor settlement, partly offset by lower Emrosi launch costs.
Cash was $22.3M at Sept. 30, 2026, versus $24.1M at Dec. 31, 2025; working capital was $25.7M versus $29.4M.
Outlook and guidance
A national plan covering over 25M lives is expected to add Emrosi to its formulary in January 2027, with impact expected to begin in Q1.
Management expects ASP to rise and gross-to-net to improve as formulary wins flow through in 2027; Q1 deductible resets may delay the benefit.
Management is considering 2027 guidance and expects caution in H1 while assessing patient mix, formulary adoption and stabilization; SG&A as a share of revenue is expected to remain steady or decrease slightly.
Latest events from Journey Medical
- Emrosi pairs Phase 3 superiority with accelerating prescriptions and broad payer access.DERM
Investor presentation - EMROSI's rapid market adoption and clinical superiority are fueling significant growth in dermatology.DERM
H.C. Wainwright 28th Annual Global Investment Conference - Q2 2026 revenue rose 23% to $18.5M, with Emrosi/EMROSI driving growth and net loss narrowing.DERM
Q2 2026 - Emrosi®'s clinical and commercial success positions it as the leading oral rosacea therapy.DERM
Investor presentation - All director nominees and KPMG as auditors for 2026 were approved; Q&A followed.DERM
AGM 2026 - EMROSI drives rapid growth, with rising revenue, margins, and expanded market access.DERM
A.G.P.'s Annual Virtual Healthcare Conference - Q1 2026 revenue up 21% to $16M, net loss narrows, and EMROSI/Emrosi® expands market access.DERM
Q1 2026 - Q2 revenue rose sequentially, profitability improved, and DFD-29 FDA review is pending.DERM
Q2 2024 - Emrosi FDA approval and launch set the stage for transformational growth in 2025.DERM
Q4 2024